TFF2 and susceptibility to pneumonia measurement: A randomized clinical trial of 80 patients with moderate COVID-19 and pneumonia found that aerosol inhalation of IFN-ĸ (a type I IFN) combined with TFF2 anti-inflammatory polypeptide led to faster SARS-CoV-2 clearance and facilitated clinical resolution of pneumonia [199].